Nov 7, 2025 06:11AM Guggenheim Starts Foghorn Therapeutics (FHTX) at Buy

Oct 30, 2025 07:30AM Foghorn advances three protein degrader programs toward clinical trials

Oct 16, 2025 07:02AM Foghorn Therapeutics to present ARID1B degrader data at summit

May 15, 2025 04:11AM Citizens JMP Reiterates Market Outperform Rating on Foghorn Therapeutics (FHTX)

May 14, 2025 04:50PM Foghorn Therapeutics Inc. (FHTX) Misses Q1 EPS by 11c

May 1, 2025 07:03AM Foghorn Therapeutics Inc. (FHTX) Appoints Neil Gallagher and Stuart Duty to its Board

Apr 30, 2025 04:49AM Citizens JMP Reiterates Market Outperform Rating on Foghorn Therapeutics (FHTX)

Apr 23, 2025 02:53AM Citizens JMP Starts Foghorn Therapeutics (FHTX) at Market Outperform

Mar 7, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Foghorn Therapeutics (FHTX)

Jan 29, 2025 11:29PM B.Riley Starts Foghorn Therapeutics (FHTX) at Buy

Jan 24, 2025 04:08PM Foghorn Therapeutics Inc. (FHTX) Files $300M Mixed Shelf

Dec 30, 2024 07:58AM Foghorn Therapeutics Inc. (FHTX) Announces Resignation of Adam M. Koppel from Board

Dec 17, 2024 06:50AM Foghorn Therapeutics (FHTX) PT Lowered to $13 at H.C. Wainwright

Dec 16, 2024 08:32AM Foghorn Therapeutics (FHTX) PT Lowered to $14 at Jefferies

Dec 16, 2024 07:13AM Foghorn Therapeutics Inc. (FHTX) to Resume Trading at 7:30 a.m.

Dec 16, 2024 07:02AM Foghorn Therapeutics (FHTX) says efficacy threshold not achieved to support continued development of FHD-286

Dec 16, 2024 07:00AM Foghorn Therapeutics Inc. (FHTX) Halted, News Pending

Nov 4, 2024 07:21PM Foghorn Therapeutics Inc. (FHTX) Tops Q3 EPS by 12c

Sep 24, 2024 06:23AM Foghorn Therapeutics (FHTX) PT Raised to $9 at Morgan Stanley

Sep 3, 2024 07:02AM Foghorn Therapeutics Inc. (FHTX) Appoints Anna Rivkin as Chief Business Officer

Sep 3, 2024 03:57AM Jefferies Starts Foghorn Therapeutics (FHTX) at Buy

Aug 8, 2024 08:26AM Foghorn Therapeutics Inc. (FHTX) Tops Q2 EPS by 19c

Jul 29, 2024 07:04AM GSK (GSK) and Flagship Pioneering partner to discover novel medicines and vaccines